Loading…

HumanaHUMCompetitor analysis, valuation and peers

United States · USD·Health Care›Managed Health Care

US health insurer focused heavily on Medicare Advantage plans, plus military (TRICARE) and CenterWell care-delivery businesses.

Momentum strong 72
Mkt cap
$46.3B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$719M
20-day average traded
Fwd P/E
22.1×
forward earnings
ROIC−WACC
n/a
WACC 7.8%
Hurdle
-5 pp
Req g minus delivered
Official | Implied
BBB / BBB
agencies · bond market
Next earnings
84 days
10 Feb 2027
Close · USD$385.78
1D-13.0%
1W-13.6%
1M-9.7%
3M+1.3%
6M+27.2%
YTD+51.7%
1Y+66.6%
ATR %5.4%
Beta0.51
52w lowhigh16.6% off high

What Humana does

US health insurer focused heavily on Medicare Advantage plans, plus military (TRICARE) and CenterWell care-delivery businesses.

Gets a fixed monthly payment from the federal government for each Medicare Advantage member, adjusted for how sick the member is, and keeps what is left after medical bills, so cost trends and government rates drive profit. A quality star rating decides bonus payments. It also runs TRICARE military health plans in the East region.

Products and services

  • Medicare Advantage plans
  • CenterWell (primary care/home health/pharmacy)
  • Group/military health plans

Customers

  • Medicare-eligible seniors
  • Military members/families
  • Employers

Where it sits in the supply chain

  • Healthcare
  • Managed care/health insurance
  • Medicare-focused payer

What could go right

  • Medicare Advantage enrollment growth
  • CenterWell care-delivery expansion

What could go wrong

  • Medicare Advantage star-rating/reimbursement risk
  • Elevated medical cost trend among seniors

Moat: narrow (scale, distribution, data). One of the largest Medicare Advantage franchises with deep broker/provider distribution.

Headquarters: Louisville, Kentucky, USA · Founded: 1961 · Employees: 67,060

Named competitors

Humana at a glance

Size Humana (HUM) is a United States Health Care company (Managed Health Care) with a market value of $46.3B, the 270th largest of 3,085 United States companies the cockpit tracks. Shares closed at $385.78 on 18 Nov 2026.

Performance Over six months the shares gained 27.2%, against +1.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 8 in its peer set.

Growth Revenue grew 22.0% over the last twelve months (peer median +6.8%); the operating margin is 1.5% (peer median 3.8%).

Valuation It trades at 22.1× forward earnings against a peer median of 13.4× (2nd most expensive of 7).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -5 pp: the price already allows for a slowdown.

Credit Humana has 18 bonds outstanding ($12.0B), rated BBB by the agencies and trading like BBB at a weighted spread of 106 bp.

Short interest Short interest is 2.3% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026HUM 127Peer median 103
Six months, rebased to 100: Humana against the median of its 7 peers (local-currency closes).

Humana financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$154B$130B$118B$106B$92.9B
Revenue growth—+10%+11%+15%—
Net income$1.25B$1.19B$1.21B$2.49B$2.81B
Free cash flow$3.14B$375M$2.39B$2.98B$3.47B
Capital expenditure$592M$546M$575M$1.00B$1.12B
Total debt$12.5B$12.9B$12.3B$12.3B$11.8B

Quarterly statements and history in the cockpit →

Humana competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%-15%-10%-5%CNCCIELVMOHOSCRUNHALHCHUM6-month return →1-month return →
Up and to the right = strong over both horizons. Humana is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×15×20×25×CNCCIELVMOHOSCRUNHHUMRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Humana is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%CNCCIMOHOSCRALHCHUMGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Humana is the large dot.

Humana competitors and peer comparison

Head to head with its named competitors (HUM vs UNH vs CVS vs ELV)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Humana HUM$46.3B+27%+22%2%22.1×5.5%
UnitedHealth UNH$314B-8%+3%5%15.4×3.1%
CVS Health CVS$104B-13%+7%4%9.6×-3.8%
Elevance Health ELV$86.6B+2%+4%4%13.9×4.3%
Centene CNC$33.4B+16%+10%1%12.8×1.0%

How Humana compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Humana against its 7 peers (data as of 18 Nov 2026)
MeasureHUMPeer medianRank in peer set
1-month return-9.7%-8.9%4th lowest of 8
6-month return+27.2%+1.6%highest of 8
Distance from 52-week high-16.6%-15.7%4th lowest of 8
Revenue growth (TTM)+22.0%+6.8%3rd highest of 8
Operating margin1.5%3.8%4th lowest of 8
Forward P/E22.1×13.4×2nd most expensive of 7
Growth the price implies (Req g, 7 yrs)5.5%3.1%3rd most demanding of 8
Growth delivered (Del g)+10.9%+11.9%2nd lowest of 8
Hurdle (Req g minus delivered)-5.5 pp-10.9 pp2nd most demanding of 8
Bond spread106 bp92 bp3rd widest of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Humana HUMUnited States$46.3B+27%+22%2%22.1×5.5%+10.9%
Centene CNCUnited States$33.4B+16%+10%1%12.8×1.0%+11.9%
Cigna CIUnited States$75.2B+1%+7%4%8.8×-3.8%+11.4%
Elevance Health ELVUnited States$86.6B+2%+4%4%13.9×4.3%+10.3%
Molina Healthcare MOHUnited States$10.8B+13%-1%1%24.7×27.2%+18.7%
Oscar Health OSCRUnited States$7.54B+18%+55%5%10.6×-19.7%+90.8%
UnitedHealth UNHUnited States$314B-8%+3%5%15.4×3.1%+11.7%
Alignment Healthcare ALHCUnited States$1.41B-60%+36%1%n/a12.2%+32.7%

Humana bonds and credit

Humana has 18 bonds outstanding with $12.0B face value. The agencies rate it BBB; its bonds trade like BBB. Weighted yield 5.92%, a spread of 106 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Humana's main competitors?
Named competitors: UnitedHealth Group (UNH), CVS Health (CVS), Elevance Health (ELV), Centene Corporation (CNC). The cockpit's measured peer set (industry) also includes Centene (CNC), Cigna (CI), Elevance Health (ELV), Molina Healthcare (MOH), Oscar Health (OSCR), UnitedHealth (UNH).
Is Humana expensive compared with its peers?
On forward p/e it trades at 22.1× against a peer median of 13.4×, 2nd most expensive of 7 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Humana stock performed?
Over six months to 18 Nov 2026 the shares returned +27.2% against +1.6% for the median peer; over one year +66.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.